ERBB2 and neoplasm: In a preclinical model of mice bearing two different HER2-positive tumor models, tumor control was enhanced when anti-HER2 CAR T cells were administered together with an anti-PD-1 antibody without causing autoimmune pathology in healthy HER2-expresssing tissue [73].